Summary

Fecal Calprotectin Test Market Growth & Trends

The global fecal calprotectin test market size is expected to reach USD 9.55 billion by 2030, registering a CAGR of 11.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of colorectal cancer, which has become one of the most common forms of cancer worldwide, is the major factor for the market growth. As healthcare systems continue to prioritize early detection to improve patient outcomes and reduce healthcare costs, fecal calprotectin testing has emerged as an essential tool for identifying inflammation in the gastrointestinal tract, which can be an early indicator of colorectal cancer. The test, which measures the concentration of calprotectin in stool samples, provides healthcare professionals with valuable information to determine whether further diagnostic procedures, such as colonoscopies, are necessary. This non-invasive approach offers a significant advantage over traditional diagnostic methods, making it a preferred option for both patients and healthcare providers.

Another significant factor contributing to the growth of the fecal calprotectin test market is the increasing prevalence of inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. These chronic conditions, which cause inflammation in the digestive tract, require ongoing monitoring and management. Fecal calprotectin tests plays a crucial role in assessing disease activity and monitoring treatment response in patients with IBD. As the global incidence of IBD rises, particularly in developed countries, the demand for reliable, non-invasive diagnostic tools like fecal calprotectin tests is expected to increase. The ability to monitor disease progression and flare-ups without the need for invasive procedures is a key advantage that is driving the adoption of this test among healthcare providers and patients.

The growing awareness of the importance of preventive healthcare is also a significant factor driving the market. Governments, healthcare organizations, and advocacy groups are increasingly focusing on the early detection of colorectal cancer and other gastrointestinal disorders. National screening programs for colorectal cancer are being implemented in many countries, and fecal calprotectin tests are often included as part of these programs. As more individuals undergo routine screening, the demand for fecal calprotectin test is expected to rise. Additionally, as the general population becomes more aware of the risks associated with colorectal cancer and IBD, there is a growing demand for diagnostic tests that can detect these conditions early, further fueling market growth.

Technological advancements in fecal calprotectin test is also contributing to the market’s expansion. The development of more accurate, faster, and user-friendly testing devices has made fecal calprotectin tests more accessible and efficient. Innovations such as automated analyzers and home testing kits have made it easier for both healthcare providers and patients to use this diagnostic tool. Automated systems, in particular, have streamlined the testing process, allowing for higher throughput in clinical laboratories and improving the efficiency of testing. Home test kits, on the other hand, provide patients with a convenient way to monitor their gastrointestinal health in the comfort of their own homes. These advancements are helping to drive the adoption of fecal calprotectin tests, particularly in regions where healthcare access may be limited or where patients prefer to manage their health independently.

Key players in the market are focusing on technological advancements, such as the development of user-friendly, automated systems that streamline the testing process and improve throughput in clinical settings. Additionally, there is a growing trend toward home-based testing solutions, with companies like BIOHIT Healthcare introducing self-test kits that allow patients to monitor their condition remotely. The market is also witnessing an increase in partnerships, collaborations, and acquisitions as companies seek to expand their product portfolios and strengthen their market presence. Competitive strategies are heavily influenced by the need to improve test sensitivity, reduce costs, and enhance patient convenience, with companies continuously working to differentiate their products in an increasingly crowded market.

Fecal Calprotectin Test Market Report Highlights

• Based on assay, enzyme-linked immunosorbent assay accounted for the largest revenue share of 66.4% in 2024. One of the primary reasons for its dominance is its high sensitivity and specificity, which allows for accurate detection of inflammation associated with gastrointestinal disorders such as inflammatory bowel diseases (IBD) and colorectal cancer

• Based on application, inflammatory bowel disease dominated the market and accounted for the largest share of 66.0% in 2024.This can be attributed to the increasing prevalence of the disease in emerging as well as developed nations

• Based on end-use, the hospitals and clinics segment dominated the end use segments with the largest market share of 54.7% in 2024. The segment dominance is attributed to large patient volumes being tested in hospitals

• North America dominated the global market due to the presence of a large number of major market players. North America has a high prevalence of IBS and other gastric diseases. Furthermore, well-developed healthcare infrastructure fuels regional market growth

• Asia Pacific is expected to witness the fastest growth with a CAGR of 12.7% over the forecast period from 2025 to 2030, due to the development of healthcare facilities across emerging markets. Furthermore, increasing focus on preventive routine testing is also supporting the market growth

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Assay
1.2.2. Application
1.2.3. End-use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Assay outlook
2.2.2. Application outlook
2.2.3. End use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Fecal Calprotectin Test Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising Prevalence of Colorectal Cancer and IBD
3.2.1.2. Growing Focus on Preventive Healthcare
3.2.1.3. Growing demand for Non-invasive Testing
3.2.2. Market restraint analysis
3.2.2.1. Limited Awareness in Some Regions
3.2.2.2. High Cost of Testing in Certain Markets
3.3. Fecal Calprotectin Test Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Fecal Calprotectin Test Market: Assay Estimates & Trend Analysis
4.1. Assay Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Fecal Calprotectin Test Market by Assay Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Enzyme-Linked Immunosorbent Assay
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.2. Enzyme Fluroimmunoassay
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Quantitative Immunochromatography
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Fecal Calprotectin Test Market: Application Estimates & Trend Analysis
5.1. Application Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Fecal Calprotectin Test Market by Application Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Inflammatory Bowel Disease
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
5.4.2. Colorectal Cancer
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Others
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Fecal Calprotectin Test Market: End-Use Estimates & Trend Analysis
6.1. End-Use Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Fecal Calprotectin Test Market by End-Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals and Clinics
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.2. Diagnostic Laboratories
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Academic and Research Institutes
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Fecal Calprotectin Test Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Target disease prevalence
7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Target disease prevalence
7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. Target disease prevalence
7.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Target disease prevalence
7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Target disease prevalence
7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Target disease prevalence
7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Target disease prevalence
7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Target disease prevalence
7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Target disease prevalence
7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Target disease prevalence
7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Target disease prevalence
7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Target disease prevalence
7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Target disease prevalence
7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. Target disease prevalence
7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Target disease prevalence
7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. Target disease prevalence
7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Target disease prevalence
7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Target disease prevalence
7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Argentina
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Target disease prevalence
7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. Target disease prevalence
7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Target disease prevalence
7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. Target disease prevalence
7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Target disease prevalence
7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company market share analysis, 2024
8.3.2. Epitope Diagnostics Inc.
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Hycult Biotech
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Actim
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Eagle Biosciences, Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. OPERON
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Svar Life Science
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. BÜHLMANN
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. DRG International Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. ALPCO
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Diazyme Laboratories
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives